

Five Factors Driving Higher Healthcare Costs

Q4 is undoubtedly busy with tasks like finalizing next year's health plan. One major trend affecting employers' decisions is **soaring healthcare costs**. Small businesses in particular are feeling the crunch.¹

While general inflation is a widely known culprit, **medical inflation** also influences healthcare costs. Here are five factors driving medical inflation that are challenging employers to **take the lead and make savvy health plan decisions for 2025**.

Factor 1: Increased labor costs

For Q1 alone this year, general labor costs across U.S. companies increased at the **fastest pace in 1.5 years**. In hospitals, **healthcare worker shortages** have increased labor costs, making patient care more expensive to provide.^{2,3}

Factor 2: Skyrocketing demand for expensive new GLP-1 drugs

Last year saw some of the **steepest drug cost hikes since 2011** for ~1,000 medications.⁴ This cost trend is driven by the popularity of GLP-1 drugs prescribed for Type 2 diabetes and weight loss.^{1,3}

Factor 3: Consolidation of providers and health systems

As our May 2024 *RAW Newsletter* reported, consolidation of providers and health systems is **driving costs up and competition down**. Nearly **70% of hospitals have merged** with health systems in recent years. These mergers have contributed to estimated **cost increases up to 65%**. The jury is still out on how consolidation affects quality and efficiency long term.⁵

Factor 4: Escalating insurance premiums

Insurers cite Factors 1-3 as key drivers of rising insurance premiums. A recent report also cites **high hospital prices** as a main driver.



Multiple factors are driving higher healthcare costs.

How can employers make the most impact?

Factor 5: Pandemic-related deferred care

During the pandemic, many patients put their healthcare appointments on hold. Deferred care has resulted in higher-severity diagnoses and longer hospital stays. This, in turn, has driven hospital labor, drug, and supply costs higher.⁸

Provide employees with real healthcare solutions that offer real value—without compromising quality.

Learn More

Regenexx has innovated such a solution for musculoskeletal (MSK) issues

Take a look at findings from the Validation Institute cost-savings analysis on Regenexx procedures⁹:



^aPatient post-procedure evaluations based on the Single Assessment Numeric Evaluation (SANE) score, a single-question patient-reported outcome measure. The SANE score is both singular and comprehensive, as it provides a concise but valuable measure of the patient's perceived function, quality of life, and goals.¹⁰

What is the **Regenex** Corporate Program?

The Regenexx Corporate Program provides **MSK cost savings for self-funded employers**. According to a Validation Institute cost-savings analysis, **procedures using Regenexx injectates were ~50% less expensive than the surgery avoided**.⁹

The program continues to see traction among employers,

brokers, and third-party administrators who have chosen to partner with us. The Regenexx benefit is no cost to add and simple to include in any self-funded healthcare plan.

Learn how adding the Regenexx benefit can **reduce costs by up to 70%** on individual surgeries while offering members a new option in care.¹¹

Contact a Regenexx Corporate // Program Sales Representative





6151 Thornton Avenue, Suite 400 Des Moines, IA 50321 regenexxcorporate.com

877-341-5968

The doctors featured are independent contractors who have licensed intellectual property from Regenexx for the preparation of medical injectates. The inclusion of these doctors is solely for informational purposes, and nothing in this newsletter content or other marketing materials should be interpreted as establishing an employer-employee relationship, partnership, or agency between Regenexx and the doctors. Likewise, these doctors are not professionally trained or licensed by Regenexx.

Cost avoidance estimates for individual groups are not reflective of the potential cost avoidance estimates for another group. Any estimate of cost avoidance for a group is specific to their employee population. To understand how your company's surgical experience may relate to the Regenexx approach, you can request a <u>Regenexx Corporate Program Impact Study</u>.

Cost savings estimates: Physicians within the licensed Regenexx network indicate the surgical procedure for which Regenexx provider patients are a candidate. The Regenexx Corporate Program then measures the actual cost of the procedure using Regenexx lab processes against the cost of the surgical alternative. While the Regenexx Corporate Program does post service reviews and assess a percentage of Regenexx provider patients, not all these cases have been verified by a third party. Fair cost estimates based on Denver, CO ZIP code. In some cases, a generic "arthroscopy" cost estimate had to be used when a detailed condition-specific estimate was unavailable.

Like all medical interventions, procedures using Regenexx lab processes have a success and failure rate. Regenexx provider patient reviews and testimonials in this email should not be interpreted as a statement on the effectiveness of regenerative therapy for anyone else. Industry professional reviews and testimonials reflect the experience of that entity with the Regenexx Corporate Program. To discuss what a partnership with Regenexx could look like for your company or client, <u>contact our team</u>.

The information provided by Regenexx is for informational purposes only and is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Regenexx is not a teaching institution or medical practice, and does not engage in the training of physicians or the practice of medicine. Physicians listed on the Regenexx websites are independent contractors who have licensed certain Regenexx intellectual property. Nothing on the Regenexx webpages, the Regenexx blog, any informational videos, or other marketing materials should be interpreted as endorsing a particular physician or establishing an employer-employee, partnership, or agency relationship between Regenexx and any physician.

References

1. Simon R. Small businesses make hard choices as insurance costs surge. *Wall Street Journal.* August 4, 2024. Accessed September 13, 2024. <u>https://www.wsj.com/business/logistics/small-business-insurance-cost-a12264a2?</u>

2. Bartash J. Labor costs rose at fastest pace in a year and a half, ECI shows, in setback to Fed's effort to tame inflation. MarketWatch website. April 30, 2024. Accessed September 13, 2024. <u>https://www.marketwatch.com/story/employee-costs-rise-at-fastest-pace-in-a-year-and-a-half-1a89ae02</u>

3. PwC. *Medical cost trend: behind the numbers 2025.* 2024. Accessed September 13, 2024. <u>https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.html</u>

4. Alltucker K. Why drugmakers have raised prices on nearly 1,000 drugs so far this year. USA Today. January 30, 2023. Accessed September 13, 2024. <u>https://www.usatoday.com/story/news/health/2023/01/30/drug-price-increases-2023/11084913002/</u>

5. Levinson Z, Godwin J, Hulver S, Neuman T. Ten things to know about consolidation in health care provider markets. Kaiser Family Foundation. April 19, 2024. Accessed May 3, 2024. https://www.kff.org/health-costs/issue-brief/ten-things-to-know-about-consolidation-in-health-care-provider-markets/

6. Marketplace insurers are proposing a 7% average premium hike for 2025 and pointing to rising hospital prices and GLP-1 drugs as key drivers of costs. News release. Kaiser Family Foundation. August 5, 2024. Accessed September 13, 2024. <u>https://www.kff.org/affordable-care-act/press-release/marketplace-insurers-are-proposing-a-7-average-premium-hike-for-2025/</u>

7. Kanimian S, Ho V. Why does the cost of employer-sponsored coverage keep rising? *Health Aff Sch.* 2024;2(6):qxae078. Published 2024 Jun 4. doi:10.1093/haschl/qxae078

8. American Hospital Association. *Pandemic-driven deferred care has led to increased patient acuity in America's hospitals.* August 2022. Accessed September 13, 2024. <u>https://www.aha.org/system/files/media/file/2022/08/pandemic-driven-deferred-</u> <u>care-has-led-to-increased-patient-acuity-in-americas-hospitals.pdf</u>

9. Validation Institute. Validation Report. 2023. Accessed May 14, 2024.

10. Hawkins RJ, Boes N, Thigpen CA, Shanley E, Pill SG, Kissenberth MJ. Measure what matters: Single Assessment Numeric Evaluation (SANE) score as the critical measure for shoulder outcomes. *J Shoulder Elbow Surg.* 2024;33(6):1397-1403.

11. Regenexx data on file.

Regenexx will never sell your information and is committed to your privacy. Read about our <u>Privacy Policy</u>, the way we use information, and our commitment to data security.

If you decide that you're no longer interested in receiving the Regenexx at Work Newsletter, we'll be sorry to see you go. Please reply to this email to let us know you'd like to opt out of receiving future issues of the Regenexx at Work Newsletter.

